Effectiveness of rAd26-rAd5, ChAdOx1 nCoV-19, and BBIBP-CorV vaccines for risk of infection with SARS-CoV-2 and death due to COVID-19 in people older than 60 years in Argentina: a test-negative, case-control, and retrospective longitudinal study
Study (n=1,282,928) found good vaccine effectiveness after 2 doses for all three vaccines (odds ratio of SARS-CoV-2 infection vs control: rAd26-rAd5 vector vaccine = 0.36, 95%CI 0.35-0.37, ChAdOx1 [AZ] vaccine = 0.32, 0.31-0.33, BBIBP [Sinopharm] = 0.56, 0.55-0.58).
Source:
The Lancet
SPS commentary:
A related commentary notes the findings provide reassurance that these lower profile vaccines offer important prevention benefits, including in people older than 60 years who had not been adequately recruited in primary studies of the vaccines.